A series of 2-(4-(methylsulfonyl)phenyl)-1-substituted-indole derivatives 4a-f was designed and synthesized as indomethacin analogs; All synthesized compounds were assessed for their in vitro COX-2 inhibition effect as well as in vivo anti-inflammatory activity using indomethacin as a reference drug. All synthesized compounds showed good anti-inflammatory activity and more selectivity for COX-2 inhibition. A molecular modeling study was carried out and the results were compatible with that derived from in vitro COX-2 inhibition assays.
INTRODUCTION
The pharmacological effect of non-steroidal antiinflammatory drugs (NSAIDs) is due to their inhibition of cyclooxygenase enzymes that catalyze arachidonic acid biotransformation to the inflammatory mediators (prostaglandins and thromboxanes) (Brune and Patrignani, 2015; Bruno et al., 2014; Pountos et al., 2012) . There are two types of cyclooxygenase enzyme; constitutive form (COX-1), which is responsible for the maintenance of physiological functions such as protection of gastric mucosa and kidney (Jutti Levita et al., 2010; Kirkby et al., 2016; Van Breemen et al., 2011) and the inducible form (COX-2) which is produced due to inflammatory stimuli (Pathak et al., 2014; Regulski et al., 2016) .
Peptic ulcer and bleeding are the major side effects of traditional NSAIDs such as aspirin I and indomethacin II (Wehling, 2014) , that is due to non-selective inhibition of COX enzyme, so selective COX-2 inhibitor drugs such as valdecoxib III, celecoxib IV, and rofecoxib V relief inflammation and pain without any gastric problems (Sostres et al., 2013) (Fig. 1) . Cardiovascular side effects associated with the use of selective COX-2 inhibitors led to the withdrawal of rofecoxib and valdecoxib from the market (Harirforoosh et al., 2014) .
Indomethacin is effective NSAIDs which used in the treatment of osteoarthritis and ankylosing spondylitis (Kaur et al., 2012) . It is one of the most ulcerogenic NSAIDs (Bandgar et al., 2011) due to its high selectivity for COX-1 inhibition.
From the previous literature, there are two strategies to overcome the gastric side effects of indomethacin; the first one is the presence of nitric oxide donating group attached to indomethacin which protects gastric mucosa and also decreases cardiovascular problems associated with selective COX-2 inhibitors (coxibs) (Abdellatif et al., 2016b; Lakshman et al., 2016) , the second strategy aimed to maintain the great activity of indomethacin by keeping the main structure of indomethacin and modifying of the structure by adding side groups to try to increase the selectivity for COX-2 inhibition and decrease its acidic nature.
The current work presents synthesis, in vitro cyclooxygenase (COX) inhibition screening, in vivo antiinflammatory activity study, and molecular docking for a series of synthesized compounds as indomethacin analogs in which: (i) chlorobenzoyl moiety of indomethacin at position 1, which is important for anti-inflammatory activity (Chowdhury et al., 2010) was replaced by 4-substituted benzyl moiety (4a-f); (ii) replacement of methyl group in position 2 by 4-methyl sulphonyl phenyl moiety, which increases interaction and subsequently increases selectivity with hydrophobic residue of COX-2 active site; (iii) removal of acidic center (CH 2 COOH) moiety in position 3 and replaced by hydrogen atom which will decrease acidity and ulcerogenic effect of resulted compounds; and (iv) methoxy group in position 5 was replaced with H, CH 3 , or F (Fig. 2) .
MATERIALS AND METHODS

Instrument and reagents
Melting points were determined on a Thomas-Hoover capillary apparatus and were uncorrected. Infrared (IR) spectra were recorded as films on NaCl plates using a Nicolet 550 Series II Magna FT-IR spectrometer. Thin-layer chromatography (TLC) (on aluminum plates coated with silica gel 60 F254, 0.25-mm thickness; Merck, Darmstadt, Germany) was used for checking the progress of 
13
C NMR spectra were carried out on Burker 100 MHZ spectrophotometer, Faculty of Pharmacy, Beni-Suef University, Egypt, using TMS as internal standard and chemical shifts were recorded in ppm on δ scale. Elemental analyses for C, H, and N were performed on PerkinElmer 2400 analyzer (Perkin-Elmer, Norwalk, CT) at the elemental analyses unit of Al Azhar University, Egypt and all synthesized compounds were ranged ±0.4% of the theoretical values. All other reagents, from the Aldrich Chemical Company (Milwaukee, WI), were used without additional purification. 4-methylthioacetophenone and 4-methylsulfonylacetophenone were prepared according to a previous procedure (Raju and Basavaraju, 2013; Yu et al., 2012) .
General procedure for synthesis of 5-substituted-2-(4-(methylsulfonyl)phenyl)-1-substituted-indole 4a-d
A solution of 5-substituted-2-(4-(methylsulfonyl) phenyl)-1-substituted-indole (3a-c) (2.5 mmol) and NaH (0.1 g, 4.5 mmol) in dry DMF (N,N-Dimethylformamide) (5 ml) was stirred for 30 minutes at room temperature. Then slowly add the substituted benzyl chloride at zero temperature and allow the reaction mixture to stir at room temperature overnight. The reaction mixture was poured into ice cold water, the precipitated solid was filtered, dried, and recrystallized from ethanol (yield: 50%-75%). 104.57, 111.31, 119.93, 121.18, 122.98, 126.26, 127.63, 127.70, 127.90, 128.12, 129.87, 131.50, 136.94, 137.47, 137.61, 139.73, and 140.42 . Anal. Calcd for C 22 H 19 NO 2 S: C, 73.10; H, 5.30; N, 3.88. Found: C, 72.94; H, 5.43 ; N, 4.01.
1-Benzyl-2-(4-(methylsulfonyl)phenyl)-1H-indole (4a)
Brown
1-(4-Chlorobenzyl)-2-(4-(methylsulfonyl)phenyl)-1H-indole (4b)
Yellow solid; Yield 55%; mp 105°C-106°C; IR (KBr) 3036 (CH aromatic)2926, 2857 (CH aliphatic), 1312, 1150 (SO 2 ) cm 104.73, 111.48, 120.84, 121.24, 123.09, 127.92, 128.13, 128.24 111.31, 120.69, 124.61, 126.30, 127.58, 127.88, 128.36, 129.04, 129.39, 129.73, 137.28, 137.69, 138.58, 139.74, and 140.29 104.33, 111.24, 120.75, 124.72, 127.91, 128.21, 128.38, 129.04, 129.53, 129.73, 132.14, 137.20, 137.53, 137.62, 139.64, 140.34 104.33, 111.24, 120.75, 124.72, 127.91, 128.21, 128.38, 129.04, 129.53, 129.73, 132.14, 137.20, 137.53, 137.62, 139.64, and 140.34 105.61, 111.00, 112.73, 126.32, 127.70, 128.81, 129.97, 131.55, 135.36, 137.26, 138.27, 140.70, 141.8, 156.82, and 159.14 
1-Benzyl-5-methyl-2-(4-(methylsulfonyl)phenyl)-1H-indole (4c)
1-(4-Chlorobenzyl)-5-methyl-2-(4-(methylsulfonyl)phenyl)-1H-indole (4d)
Biological Evaluation
In vivo anti-inflammatory activity Animals
Wistar albino male rats weighing (120-140 g; received from the animal house of Nahda University, Beni-seuf, Egypt) were divided into eight groups in cages (five per cage) at laboratory temperature 25°C ± 1°C with 60% ± 10% humidity with the presence of food and water source. Procedures of animal care and treatments were carried out according to the research ethical committee protocol, Beni-suef University (2014-Beni-suef, Egypt).
COX-1/COX-2 inhibition colorimetric assay
The kit of colorimetric COX (ovine) Inhibitory Screening Assay (Kit catalog number 760111, Cayman Chemical, Ann Arbor, MI) was used according to the manufacturer's protocol as mentioned earlier (Abdelazeem et al., 2014) to measure the capability of synthesized compounds to inhibit COX-1 and COX-2 enzymes. The results are shown in Table 1 .
Carrageenan-induced rat paw edema assay
Group I (negative control) received 5% DMSO aqueous solution (v/v), Group II received indomethacin as a reference drug (10 mg/kg; po), and the other six groups received compounds 4a-f (10 mg/kg; po) in form of 5% DMSO aqueous solution.
The treatment began 1 hour before the induction of inflammation. Sub-plantar injection of 0.02 ml of 1% carrageenan (Sigma-Aldrich, USA) in normal saline was used to induce paw edema. Plethysmometer was used to determine the thickness of paw edema after 1, 3, and 5 hours from carrageenan injection (Abdellatif et al., 2016a) .
Anti-inflammatory activity was determined by the percentage of inflammation inhibition of rat paw thickness according to the following equation:
where T t is the mean increase in paw thickness in rats treated with the tested compound;
T c is the mean increase in paw thickness in rats of the control group. The results were shown in Table 2 .
Molecular modeling and docking
Molecular operating environment (MOE) version 2014.09 software was used for molecular modeling studies. The structures of 4b and 4f were prepared using MOE. Valdecoxib crystal structure with the COX-2 active site (PDB: ID 2AW1) was obtained from the protein data bank (PDB; Di Fiore et al., 2006) . Preparation of the enzyme for docking by 3D protonation, where hydrogen atoms were added to their standard geometry. The structures of 4b and 4f were docked into the COX-2 receptor through MOE-Dock using triangle matcher placement method, London dG scoring function and force field refinement was accomplished on the top 30 poses per each ligand. Re-docking of valdecoxib with 2AW1 active site to validate the docking method. Interactions of amino acids and the lengths of hydrogen bonds were illustrated in Table 3 .
RESULTS AND DISCUSSION
Chemistry
The synthesized compounds were obtained from a series of reactions demonstrated in Scheme 1. 4-methylsulfonyl acetophenone (1) reacted with substituted phenylhydrazine hydrochloride (2) in acetic acid under Fisher indole synthesis reaction conditions to yield 5-substituted-2-(4-(methylsulfonyl) phenyl)-1-substituted-indole (3a-c) (Abdellatif et al., 2016a; Zarghi et al., 2008) . A solution of indole derivatives (3a-c) with substituted benzyl chloride in DMF in presence of NaH to give desired compounds (4a-f).
All newly synthesized compounds were characterized by IR, 1 H NMR, 13 C NMR, and elemental analyses. The IR spectra showed two absorption bands at 1,312 and 1,149-1,151 cm −1 corresponding to SO 2 . Also, 1 HNMR spectra showed a singlet peak at δ 3.24-3.27 for SO 2 CH 3 . Finally, 13 C NMR spectra showed a peak at δ 43.87-43.92 for SO 2 CH 3 , peak at δ 21.53 for CH 3 for compounds 4c and 4d.
Biological evaluation
In vitro cyclooxygenase (COX) inhibitory assay
The obtained data (Table 1) for in vitro COX-1/COX-2 inhibitory assay showed that all synthesized compounds with weak selectivity for COX-1 (IC 50 = 8.1-11.8 µM) in comparison with indomethacin (IC 50 = 0.039 µM).
Otherwise, they are high selectivity of COX-2 (IC 50 = 0.11-0.2 µM) in comparison with indomethacin (IC 50 = 0.49 µM). All compounds with selectivity to COX-2 enzyme (selectivity index = 40.5-107) were more than indomethacin (SI = 0.079). Compound 4b showed the most inhibitory activity against COX-2 (IC 50 = 0.11 µM and SI = 107.63), had a chlorobenzyl and methylsulfonyl moiety which was 1,362 times more selective toward COX-2 isozyme than indomethacin (COX-2 IC 50 = 0.49 µM, SI = 0.079).
In vivo anti-inflammatory activity
The anti-inflammatory activity was monitored for all tested compounds and compared to indomethacin by using the carrageenan-induced rat paw edema test. Results were listed in Table 2 .
The results demonstrated that the compounds 4b, 4d, and 4f with the highest COX-2 inhibition activity (IC 50 = 0.11, 0.17, and 0.15 µM, respectively) showed a reduction of inflammation by 93.7%, 85.1%, and 90.7% after 6 hours, respectively, near to indomethacin (96% inhibition of inflammation after 6 hours).
Whilst the compounds 4a, 4c, and 4e with COX-2 inhibition activity (IC 50 = 0.18, 0.20, and 0.28 µM, respectively) showed good anti-inflammatory activity (76.2%, 59.4%, and 78.5% inhibition of inflammation after 6 hours, respectively) in comparison with indomethacin (96% inhibition of inflammation after 6 hours).
From the obtained results, we can conclude the following structure-activity relationships of the synthesized compounds as follows: (i) presence of phenyl methyl sulfonyl (SO 2 Me) moiety increase COX-2 inhibition activity; (ii) replacement of benzoyl group of indomethacin with benzyl group maintains antiinflammatory activity; and (iii) all p-chloro benzyl derivatives have anti-inflammatory activity higher than non-substituted benzyl derivatives.
Molecular modeling
The molecular modeling study was performed using COX-2 crystal structure (PDB ID: 2AW1) (Di Fiore et al., 2006) to show the binding mode of synthesized compounds to the COX-2 active site. Table 3 shows the results of computational docking of compounds 4b, 4f, indomethacin II, and valdecoxib III as a ligand for COX-2 enzyme using MOE 2014.09 modeling software.
Valdecoxib interacted with COX-2 through five hydrogen bonds as follows: (i) NH 2 with His119 (2.74 A°), (ii) NH 2 with Thr199 (3.46 A°), (iii) SO 2 with Leu199 (3.12 A°), (iv) SO 2 with Thr199 (2.77 A°), and (v) NH 2 with His94 (2.89 A°).
On the other hand, compound 4b had four hydrogen bonding interactions as follows: (i) SO 2 with His94 (2.85 A°), (ii) SO 2 with His96 (3.39 A°), (iii) SO 2 with Thr199 (3.35 A°), and (iv) SO 2 with Thr199 (2.79 A°). Likewise, compound 4f interacted through three hydrogen bonds as follows: (i) SO 2 with His94 (2.86 A°), (ii) SO 2 with His96 (3.38 A°), and (iii) SO 2 with Thr199 (2.84 A°). Compounds 4b and 4f showed binding interaction through the CH 3 SO 2 group with three or four hydrogen bonds. In contrast, indomethacin showed poor binding with COX-2 with one hydrogen bond, this confirms that the more selectivity of synthesized compounds than indomethacin toward COX-2 receptor.
Compounds 4b and 4f were highly bound to the COX-2 receptor (affinity in kcal/mol is −6.56 to −5.67) in comparison with valdecoxib (−4.52 kcal/mol). Finally, these docking results were well-matched with the in vitro COX-2 inhibition assays and show that the selectivity of compounds 4b and 4f against COX-2 isozyme possibly due to the presence of SO 2 Me as COX-2 pharmacophore (Figs. 3-6) . 
